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Abstract
Cell-based active immunotherapy for cancer is a promising novel strategy, with the first dendritic cell (DC) vaccine achieving
regulatory approval for clinical use last year. Manufacturing remains arduous, especially for DC vaccines, and the prospect of
using cell-based immunotherapy in the adjuvant setting or in combination with chemotherapy remains largely untested.
Here, we used a comparative oncology approach to test the safety and potential efficacy of tumor RNA-loaded, CD40-
activated B cells in privately owned dogs presenting with non-Hodgkin’s lymphoma (NHL), a clinical scenario that represents
not only a major problem in veterinary medicine but also a bona fide spontaneous animal model for the human condition.
When administered to NHL dogs in remission after induction chemotherapy, CD40-B cells electroporated ex vivo with
autologous tumor RNA safely stimulated immunity in vivo. Although chemotherapy plus CD40-B vaccination did not
improve time-to-progression or lymphoma-specific survival compared to dogs treated with chemotherapy alone,
vaccination potentiated the effects of salvage therapy and improved the rate of durable second remissions as well as
subsequent lymphoma-specific survival following salvage therapy. Several of these relapsed dogs are now long-term
survivors and free of disease for more than a year. Overall, these clinical and immunological results suggest that cell-based
CD40 cancer vaccination is safe and synergizes with chemotherapy to improve clinical outcome in canine NHL. More
broadly, our findings underscore the unique value of clinical investigations in tumor-bearing companion animals.
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Introduction
With the recent FDA approval of the dendritic cell vaccine
sipuleucel-T for the treatment of advanced prostate cancer [1],
there has been renewed efforts to further optimize second-
generation cell-based therapies aimed at stimulating anti-tumor
immunity for the treatment of cancer [2–3]. Because the use of
resting or unactivated antigen presenting cells (APC) may actually
trigger antigen-specific T cell tolerance and therefore be highly
counter-productive if administered to patients, it is critical to
develop and test APC formulations that are expressly designed to
activateAPC eitherin vivo orexvivo.Oneapproach that has emerged
is pharmacological crosslinking of CD40 expressed on the surface of
APC [4] in order to up-regulate MHC and co-stimulatory
molecules, stimulate secretion of inflammatory cytokines such as
IL-12, and up-regulate anti-apoptotic molecules – a process
collectively known as ‘‘APC licensing’’ that enables priming of
naı ¨ve CD4+ and CD8+ T cells and boosting robust memory T cell
responses [5]. Clinical reagents that activate CD40 have been
developed for systemic use and have shown clinical promise [6–8],
but these agents do not necessarily drive T cell responses in vivo
owing to restrictive features of the tumor microenvironment [8].
Here, we study an ex vivo approach to APC licensing. Although
dendritic cells in most models are the cells chiefly responsible for
physiological T cell priming in vivo, B cells can also act as APC and
can also be licensed by CD40 activation [9–10]. CD40-activated B
cells (CD40-B), like DC, can prime naı ¨ve T cell responses against
neoantigens ex vivo and can boost memory T cell responses [9–11],
suggesting that antigen-loaded, CD40-B may represent a viable
alternative to DC in cell-based vaccination strategies. In sharp
contrast to DC, however, B cells can be readily expanded in vitro
using CD40 ligation, removing the necessity of large volume
leukapheresis (as is required to manufacture sipuleucel-T) to
procure sufficient numbers of APC for recurrent vaccinations [9–
10,12]. Although CD40-B can augment antigen-specific effector T
cell responses in vitro against viral and tumor associated antigens,
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anti-tumor immune responses in vivo.
To address this question, we have performed a clinical trial of a
CD40-B vaccine in privately owned dogs (pets) with non-
Hodgkin’s lymphoma (NHL). Canine NHL represents a major
health issue in dogs and shares similar clinical, behavioral, genetic
and cytogenetic characteristics to NHL in humans. It is now
widely accepted as a clinically relevant model system in which to
evaluate safety and efficacy of novel therapeutic agents prior to
their translation into human clinical trials [13]. As in human
patients with NHL, the standard of care for the initial treatment of
canine NHL consists of combination chemotherapy protocols.
Although induction chemotherapy is highly effective and 60%–
85% of treated dogs achieve complete clinical remission following
induction therapy, nearly all dogs relapse within one year with
drug-resistant disease and die from lymphoma [14–15]. The cure
rates of canine NHL have not changed substantially over the past
decades despite the use of more dose-intense protocols.
In this study, we clinically tested a therapeutic platform that we
have previously described in preclinical studies [12] in which B cells
from NHL dogs are expanded in vitro using CD40L transfected
K562 cells (KtCD40L) and then loaded with autologous tumor
RNA to generate a cell-based vaccine. RNA-loaded CD40-B
derived from canine peripheral blood B cells stimulate functional,
antigen-specific T cell responses in vitro from healthy dogs and from
dogs with spontaneously occurring NHL [12]. The use of whole
tumor RNA as the antigenic payload allows for an HLA-
independent, whole antigen approach that aims to promote a
polyclonal anti-tumor T cell response. Here, we report the first
clinical trial in any species of a tumor RNA loaded CD40-B cancer
vaccine, performed in the setting of minimal residual disease. Our
results demonstrate that CD40-B can stimulate immune responses
in vivo that impact second remission and survival in a spontaneous,
large animal model of NHL. These results suggest that tumor
antigen loaded CD40-B may serve as a practical alternative to DC
in cell-based vaccine strategies for both dogs and humans with
cancer.
Results
Privately owned dog protocol
Thirty privately owned dogs with NHL were enrolled at disease
presentation in this pre-clinical feasibility trial and underwent
induction chemotherapy (Group 1; intent to treat). Patient
characteristics are shown in Table 1. Nineteen dogs (63%) were
confirmed to be in complete cytological and clinical remission at the
end of chemotherapy and were therefore eligible for vaccination
with autologous CD40-activated B cells (every other week for three
intradermal injections in the flank) that had been loaded with total
RNA previously isolated from autologous lymphoma cells (Methods
and Materials, and Supplemental Methods) (Group 2). An equal
number of autologous CD40-B loaded with canine distemper virus
hemagglutinin mRNA was injected in the opposite flank as an
immunological control. Sixty-four dogs with NHL were selected
from a group of 130 dogs as controls for the unvaccinated group
(Group3).These dogswereselected basedon the fact that theywere
treated with the same induction chemotherapy regimen as the
vaccinated group (Group 2) and were confirmed to be in complete
clinical and cytological remission at the end of the chemotherapy
protocol but they did not receive CD40-B cell vaccines. There were
no incentives for dogs in any group to receive chemotherapy thus
avoiding any bias in treatment approach or intensity of therapy.
Although the number of dogs in the control group (Group 3) was
larger than the vaccinated dog group (Group 2), there were no
statistically significant differences in prognostic factors including
immunophenotype between groups 2 and 3 (Table 1).
Toxicity
Vaccination with RNA loaded CD40-B was extremely well-
tolerated. One dog exhibited signs of an acute systemic reaction,
including weakness, hypotension, and vomiting within a few hours of
receiving the first vaccine. Treatment with intravenous fluids,
diphenhydramine and anti-emetics resulted in an uneventful recovery.
This particular dog was pretreated with diphenhydramine immedi-
a t e l yp r i o rt ot h e2s u b s e q u e n tv a c c i nations, and no further systemic
reactions occurred. Mild injection site reactions including erythema
and swelling occurred in several dogs. There were no significant
alterations in complete blood chemistries during oraftervaccinationin
any of the dogs. Furthermore, no long-term complications of
vaccination such as autoimmunity were identified clinically, clinico-
pathologically (monitored by serial CBCs) or at necropsy.
Clinical outcomes
Median time to disease progression (TTP) was 236 days (95%
confidence intervals [CI], 158–314 days) in Group 1 (intent to
Table 1. Canine patient characteristics.
Variable
Group 1 (intent to
treat) (n=31)
Group 2 (vaccinated)
(n=19)
Group 3 (control)
(n=64)
P-value
(Group 2 vs. 3)
Age (yrs; mean 6 SD) 8.03 (2.7) 7.6 (2.7) 7.33 (2.7) 0.73
Body weight (kg; mean 6 SD) 32.9 (13.5) 33.1 (12.7) 32.3 (13.1) 0.82
Stage n (%) n (%) n (%) 0.43
II–IV 17 (54.8%) 9 (47.4%) 27 (42.2%)
V 14 (45.2%) 10 (52.6%) 37 (57.8%)
Sub-stage n (%) n (%) n (%) 0.112
a 21 (67.7%) 14 (73.7%) 35 (54.7%)
b 10 (32.3%) 5 (26.3%) 29 (45.3%)
Immunophenotype n (%) n (%) n (%) 0.45
B 21 (67.7%) 14 (73.7%) 33 (78.6%)
T 10 (32.3%) 5 (26.3%) 9 (21.4%)
doi:10.1371/journal.pone.0024167.t001
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dogs), and 327 days (95% CI, 223–431) in Group 3 (unvaccinated
dogs). There were no statistically significant differences in TTP
between Groups 1 and 3 (p=0.16) or Groups 2 and 3 (p=0.34).
Kaplan Meier curves for TTP are shown in Figs. 1A and 2A.
Median lymphoma specific survival (LSS) was 489 days in Group
1 (95% CI, 309–669 days), 809 days in Group 2 (95% CI, 289–
1335 days), and 594 days in the Group 3 (95% CI, 536–652 days).
Kaplan Meier curves for LSS are shown in Figs. 1B and 2B.
Although there was a 36% improvement in the median LSS in the
vaccinated Group 2 compared to the unvaccinated control Group
3, the difference was not statistically significant (p=0.18).
Similarly, there was no statistically significant difference in median
LLS between Group 1 and Group 3 (p=0.37). The overall
survival rate in Group 2 and Group 3 dogs at 1 year was 89.5%
and 74.1%, respectively, and at year 2 was 41.4% and 25.4%,
respectively. There was no statistically significant difference in
overall survival, indicating that vaccination did not increase
mortality.
Fifteen of 19 (79%) vaccinated dogs in Group 2 eventually
relapsed, but 4 dogs (21%) did not and achieved a durable (.16
months) first remission after chemotherapy and CD40-B vaccina-
tion. One of these four dogs died from unrelated causes at 492
days with no evidence of lymphoma confirmed by necropsy. The
other 3 dogs are alive with no evidence of lymphoma at 959, 1103,
and 1287 days after the start of chemotherapy (with clinical follow
up ongoing). Ten of the vaccinated dogs (52.6%) have died due to
lymphoma; six remain alive in durable first or second remission,
and 3 were euthanized due to other causes. Two of the three dogs
euthanized had hemangiosarcoma, with no evidence of lympho-
ma, and the other dog was euthanized due to ‘‘declining health.’’
Limited work-up was allowed on this dog, but necropsy found no
evidence of lymphoma. The cause of declining health was not
identified; however, there was no evidence of autoimmunity and
all cell lineages with full maturation were present in the bone
marrow. A total of 7 dogs underwent necropsies when they died or
were euthanized. With the exception of the 3 previously discussed
dogs, all the other dogs (4 dogs) were euthanized due to advanced
stage lymphoma and had no evidence of late toxicities from the
vaccine. Four of the 64 dogs in the control group (Group 3) were
lost to follow-up after restaging, and outcome information was not
available. Of the remaining 60 dogs, 46 (76.7%) relapsed and 14
(23.3%) did not. There was no significant difference in relapse rate
between Groups 2 and 3 (p=1.0).
Salvage therapy and cause of death
Ten of the 15 vaccinated dogs (66.7%) in Group 2 that relapsed
were treated with cyclophosphamide, vincristine, and prednisone
(COP) as salvage therapy and four of these dogs (40%) achieved
durable second clinical remission (.22 months) and did not
relapse. The other 5 vaccinated dogs that relapsed received single-
agent prednisone as salvage therapy, one of which achieved a
durable second remission and did not relapse. Three of these four
vaccinated dogs with a chemotherapy-induced durable second
remission are still alive with no evidence of lymphoma at 689,
1209, and 1216 days after the start of their initial chemotherapy.
The two other dogs (one treated with COP chemotherapy and 1
treated with prednisone alone) were euthanized at 722 and 958
days respectively; as noted above, the first dog had hemangiosar-
coma and the second dog was euthanized due to ‘‘declining
health.’’ Neither dog had evidence of lymphoma at necropsy. The
other ten dogs relapsed during salvage therapy and were
euthanized due to their lymphoma.
Figure 1. Kaplan Meier estimates comparing intent-to-treat Group 1 to unvaccinated control Group 3 for (A) time-to-progression
(TTP) (p=0.16) and (B) lymphoma-specific survival (LSS) (p=0.37).
doi:10.1371/journal.pone.0024167.g001
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were treated with salvage chemotherapy and one dog received
prednisone alone; however, only 3 (7.7%) of the dogs in Group 3
that received salvage therapy achieved a durable second remission,
compared to 40% of vaccinated dogs that achieved a durable
second remission to salvage therapy, a difference that was
statistically significant (p=0.025). This difference resulted in a
statistically significant improvement in survival after salvage
therapy for relapsed Group 2 dogs receiving salvage therapy
compared to relapsed Group 3 dogs who received salvage therapy
(p=0.038) (Fig. 3). Importantly, there was no significant difference
in the use of salvage therapy between dogs that relapsed in Group
2 (66.7%) and Group 3 (84%), (p=0.15).
Immunological assessment
To determine whether tumor RNA-loaded CD40-B cells
induced functional tumor-specific T cell responses in vivo,
peripheral blood mononuclear cells (PBMC) obtained at the time
of diagnosis and 3 weeks after the last vaccination were analyzed
for the presence of IFN-c producing, tumor-specific T cells by
ELISPOT. IFN-c ELISPOT analysis was available for 9 dogs in
Group 2 (Fig. 4). A positive IFN-c response to therapy was defined
as .50% increase in the number of cytokine secreting cells after
vaccination compared to baseline and with a p value ,0.05.
Positive immune responses to CDV HA were observed in 4 of 9
vaccinated dogs; a positive IFN-c immune response to autologous
tumor antigen was also observed in 1 dog and a trend towards
significance (p,0.1) was observed in another 2 dogs. In 2 other
dogs (dog 1 and dog 16) there was .50% increase in the number
of cytokine secreting cells in response to autologous tumor antigen
after vaccination compared to baseline, but statistical significance
Figure 2. Kaplan Meier estimates comparing vaccinated Group 2 to unvaccinated control Group 3 for (A) TTP (p=0.34) and (B) LSS
(p=0.18).
doi:10.1371/journal.pone.0024167.g002
Figure 3. Kaplan Meier estimates for lymphoma-specific
survival (LSS) of relapsed dogs who received salvage therapy,
demonstrating statistically significant differences between
vaccinated Group 2 to unvaccinated control Group 3
(p=0.038).
doi:10.1371/journal.pone.0024167.g003
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analysis. There was no correlation between immunological
response and the average number of CD40-B cells administered
to each dog over the course of the three vaccinations. Because only
9 dogs were able to be analyzed (due to insufficient availability of
PBMC at all time points), we were unable to detect a statistically
significant correlation between immunological response and
clinical outcome.
Discussion
The aim of this study was to determine whether tumor RNA-
transfected CD40-activated B cells could safely induce anti-tumor
immunity and impact the natural history of spontaneous NHL in
dogs after remission induction with chemotherapy. In a clinical
trial of privately owned dogs, RNA-loaded autologous CD40-B
cells administered intradermally in the setting of minimal disease
functioned as APC in vivo and stimulated IFN-c secreting cells.
Although our vaccination approach did not impact TTP or LSS
when compared to a control group of dogs treated with
chemotherapy alone, we observed a statistically significant
improvement in the vaccinated group in the rate of durable
second remissions as well as subsequent lymphoma-specific
survival in relapsed dogs following treatment with salvage therapy.
This finding is particularly intriguing because the salvage therapy
used included only drugs that had already been used in the initial
chemotherapy regimen. It has long been appreciated that the vast
majority of dogs with NHL that relapse after initial remission
suffer rapid tumor progression and die despite salvage treatments
[15]. As an illustration of this, in the chemotherapy (no vaccine)
group in this study, durable second remission was achieved in only
7.7% of dogs. In contrast, for dogs that relapsed after receiving
chemotherapy plus CD40-B vaccination, 40% of dogs achieved a
second, durable remission. Moreover, lymphoma-specific survival
was longer in relapsed dogs that had been previously vaccinated
than those dogs that had not (with active clinical follow-up
ongoing). Although the number of dogs in the vaccinated group is
small, the clinical findings in this feasibility trial are encouraging
and warrant further testing in a larger, double-blinded, random-
ized clinical trial. Overall, our clinical and immunological results
suggest that cell-based CD40 cancer vaccination synergizes with
chemotherapy to improve clinical outcome in this disease.
The vaccine strategy employed in this study builds on our
previous preclinical work [10,12] demonstrating that CD40-B may
be used as analternative toDCincancer vaccine strategies, with the
added benefit of ex vivo cell expansion allowing multiple vaccines to
be generated from a small volume of peripheral blood. Our results
confirm that the use of whole tumor RNA transfected CD40-B cells
as an alternative to DC vaccination is both feasible and well
tolerated in vivo. In this study we used whole tumor RNA as the
antigenic payload that supplies both mutated tumor/lymphoma
specific antigens and non-mutated self-antigens. In vitro, RNA-
transfected CD40-B can stimulate cytotoxic T cell responses against
tumor antigens that are comparable with responses induced by
antigen-loaded DC [10,16]. Here, we have translated these findings
into the clinical arena and show that, similar to antigen-loaded DC,
CD40-B can induce immune responses when administered in vivo.
Importantly, we found that autologous RNA loaded CD40-B could
be administered safely to dogs with only occasional and mild
injectionsite reactionsnoted as acute adverse events.One doghad a
single anaphylactic-like reaction to the first vaccination which did
not occur following the second or third vaccination. No long-term
complications of vaccination including autoimmunity were identi-
fied either clinically or at necropsy in any of the dogs. Furthermore,
we also evaluatedoverall survival betweenthe vaccinated group and
the control group and found no statistically significant difference,
indicating that vaccination did not increase mortality.
Our observations that prior CD40-B vaccination positively
impacts the rate of second remission and subsequent survival in
relapsed dogs treated with salvage therapy parallels findings that
are emerging from recent work in human vaccine trials; namely,
prolonged median overall survival [1] or an unexpected high
response rate to salvage therapy [17], without necessarily
improving progression free survival in human patients vaccinated
with antigen-loaded DC. These human studies documented an
association between early immune responses to vaccination and
unexpected and durable responses to later chemotherapy, and
suggest a complex interaction between chemotherapy and
immunotherapy that may be therapeutically exploitable. Although
the underlying mechanisms behind these observations are not
completely understood, it is hypothesized that the use of cytotoxic
chemotherapy in patients whose immune systems have been
appropriately primed to recognize tumor antigen via cancer
vaccination can augment anti-tumor immunity [18–19]. Cytotoxic
agents such as the anthracyclines may induce ‘‘immunogenic’’
tumor cell death and the release of potent pro-inflammatory
molecules that promote DC activation and antigen processing and
presentation [20]. Moreover, the cytotoxic effects of salvage
Figure 4. RNA loaded CD40-B cells stimulate antigen-specific IFN-c responses in PBMCs. PBMCs were obtained from dogs at the time of
diagnosis (pre) and 3 weeks post vaccination (post) and antigen-specific immune responses directed against (A) CDV-HA and (B) lymph node tumor
antigens were determined by IFN-c ELISPOT. *p,0.1, **p,0.05.
doi:10.1371/journal.pone.0024167.g004
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by breaking down tumor cells and thereby releasing tumor
antigens for presentation [21]. Very recent data also suggest that
chemotherapy may sensitize tumor targets for killing by specific T
cells induced by vaccination [22]. Cytotoxic agents such as
cyclophosphamide may also enhance anti-tumor immunity
through inhibition of regulatory T cells [23] and by modulating
the balance of dendritic cell subsets in lymphoid organs [24].
Thus, in our study, it is possible that salvage therapy served to
augment anti-tumor immune responses that had been appropri-
ately primed by prior CD40-B vaccination, leading to durable
second remission times and prolonged overall survival.
We used data from dogs treated with the same chemotherapy
protocol at the same institution as the control population in the
TTP/LSS analyses. Ideally, the control population would have
consisted of dogs randomized to receive chemotherapy alone, and
the comparisons performed on intent-to-treat basis; however, as
many as 40% of dogs presenting to our institution with NHL fail
induction chemotherapy and would therefore not be eligible for
vaccination or inclusion in the control population. The sample size
required to have adequate power for such a study would be quite
large and therefore not practical for a feasibility study. As an
alternative, we selected dogs with the same disease, treated with the
same 20-week chemotherapy regime that led to a complete
remission from a larger group of dogs with NHL as an unvaccinated
control group. Importantly, by analyzing previously documented
negative prognostic factors between groups 2 and 3 (Table 1), we
confirmed that there was no statistical difference in these factors
between groups 2 and 3. However, due to the small population size
of group 2 and the diversity of variables it is possible that differences
in negative prognostic factors between the groups may have existed.
Finally, our findings underscore the value of a comparative
oncology approach [13,25] in which privately owned dogs with NHL
represent not only a major clinical problem in veterinary medicine
but also a spontaneous animal model for the human condition. The
testing of novel immune therapies in the high-risk but minimal
residual disease setting in dogs is appropriate and ethical, and
potentially crucial for the successful development of immunological
approaches that would otherwise be suppressed by large tumor
burdens. Here, rather than deploying complex therapeutic efforts to
address issues of immunosuppression in the tumor microenviron-
ment, we first used standard chemotherapy to massively decrease the
tumor burden prior to immune therapy. In the vast majority of phase
I clinical trials that evaluate immune therapies in humans, patients
have significant tumor burden, advanced disease, and have suffered
the immunosuppressive effects of multiple rounds of chemotherapy
and other treatments. The study of dogs with spontaneous NHL
provides a unique opportunity to evaluate the therapeutic efficacy of
immune therapies in the setting of minimal residual disease. The
results from this study suggest that synergistic effects between
chemotherapy and immunotherapy occur and that the optimal
combination of these modalities may lead to significant therapeutic
responses. Further studies in privately owned dogs with naturally
occurring cancers may provide an opportunity to understand the
underlying mechanisms behind this effect and to determine the
optimal combination and sequence of chemo-immunotherapy for
therapeutic success. This approach may speed the translation of such
combinations to human patients.
Materials and Methods
Ethics Statement
The study was approved by our university’s Institutional Animal
Care and Use Committee (Protocol 800900) and the Privately
Owned Animal Protocol Committee of the University of
Pennsylvania School of Veterinary Medicine (Protocol POAP-
197).
Protocol study population, eligibility criteria and study
design
Dogs with newly diagnosed, untreated multicentric NHL that
weighed more than 5 kg were screened for eligibility to participate
in this study. At the time of diagnosis, complete staging, including
CBC, serum chemistry profile, urinalysis, thoracic radiographs,
abdominal ultrasound, immunophenotyping, bone marrow aspi-
rates, lymph node aspirates and biopsies, was performed.
Eligibility criteria included no serious concurrent disease, less
than 30% lymphoblasts on bone marrow aspirates, rare to absent
lymphoblasts detected on peripheral blood smear review, and
written informed consent from the owner.
Prior to induction chemotherapy a single, peripheral lymph
node was surgically excised, and peripheral blood was collected for
vaccine generation and baseline immune function studies.
Induction chemotherapy consisted of a short, 20-week combina-
tion chemotherapy protocol including cyclophosphamide, doxo-
rubicin, vincristine, L-asparaginase, and prednisone, as previously
described [14]. The same induction chemotherapy protocol was
used for dogs in groups 2 and 3. All dogs underwent complete
restaging, including fine needle aspirates and cytological evalua-
tion of a peripheral lymph node, two weeks after completion of the
protocol. Only dogs that were confirmed to be in complete
remission were eligible for vaccination and only these dogs
underwent further blood draws for PBMC collection.
The autologous vaccine consisted of total tumor RNA-loaded
CD40-B cells and the control vaccine consisted of CD40-B cells
loaded with CDV-HA mRNA. Vaccinations were initiated 3 to 4
weeks after completion of chemotherapy. Vaccinated areas were
shaved and aseptically prepared prior to vaccination. Vaccines
were given intradermally (tumor RNA CD40-B in one flank;
CDV-HA CD40-B in the opposite flank) every 2 to 3 weeks for a
total of three vaccinations. Blood for immune studies and toxicity
monitoring was collected immediately prior to each vaccination
and 3 weeks after the last vaccine was given.
Dogs that failed to achieve remission and therefore did not
receive the vaccine and dogs that were vaccinated, but relapsed
later were offered standard-of-care salvage therapy according to
their owners’ preference and veterinarian recommendations. All
vaccinated dogs were monitored for relapse through monthly
examinations for the first year, every other month for the 2
nd year
and every 3 months for the third year. Relapses were confirmed by
fine needle aspirates in all dogs.
RNA and mRNA preparation
Manufacturing details for CD40-B preparation, RNA isolation
and electroporation have been previously reported [12]. In brief,
total RNA was extracted from malignant lymph node tissue taken
at the time of diagnosis and prior to chemotherapy using the
RNAeasy kit (Qiagen, Valencia, CA). RNA quantity was
determined by measuring O.D. at 260 nm and RNA quality was
determined by gel electophoresis. RNA was stored at 280uC prior
to use. mRNA encoding full-length CDV-HA or GFP was
prepared from template plasmids by in vitro transcription as
previously described [12]. Transcribed RNA was polyadenylated
at the 39 terminus using the Escherichia coli Poly(A) Polymerase I
(E-PAP), treated with DNAse to remove plasmid sequences and
purified by acidic phenol/chloroform extraction and RNeasy
column separation (Qiagen).
CD40-B Cell Vaccine for Canine Lymphoma
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CD40-B were generated from canine peripheral blood mono-
nuclear cells (PBMC) using K562 cells transfected with human
CD40L (KtCD40L) as feeder cells as previously described [12].
5610
6 PBMCs were co-cultured with 10
6 lethally irradiated
KtCD40L cells in the presence of recombinant canine IL-4 and
cyclosporine. After 5–7 days, B cells were harvested, counted and
re-stimulated with irradiated KtCD40L cells in the presence of IL-
4 and cyclosporine. Cells were stimulated with KtCD40L cells
three times. Five days following the last stimulation CD40-B
harvested, washed twice in PBS and resuspended at 2610
6 cells
per 100 ul of Nucleofector B solution (Amaxa, Cologne,
Germany). Up to 5610
6 cells were electroporated with either
10 ug autologous tumor RNA or 2 ug CDV mRNA using the
Amaxa Nuceofector device (pulse program U08). The electro-
porator was designed and manufactured according to GMP
standards set by the FDA and is approved for use in human
vaccine manufacturing. Following electroporation, cells were
washed once in B cell media and then twice in PBS.
Electroporated cells were resuspended in 300 ul of PBS and
administered intradermally over the right flank for tumor RNA-
loaded CD40-B cells and over the left flank for CDV-loaded
CD40-B cells.
Vaccine preparation and generation
CD40-B cells and tumor RNA were generated from all dogs
although the number of CD40-B cells produced varied per dog.
Dogs received the same number of RNA-loaded CD40-B cells for
CDV and tumor vaccination and the majority of dogs were
vaccinated with CD40-B cells in the target range of 1610
6 to
5610
6 cells. In three dogs, B cells did not expand well using the
KtCD40L culture system and CD40-B cell vaccine doses were less
than 10
6 cells per vaccine. Following electroporation both CDV
and tumor RNA loaded CD40-B cells for each dog were submitted
for aerobic and anaerobic bacterial culture and fungal culture to
determine the presence of microbial contaminants. Of the 114
vaccines generated, two (from the same batch of CD40-B cells)
tested positive for non-fermenting gram negative bacilli. Fungal
cultures from all vaccines were negative. All dogs except for one,
received vaccines as scheduled every three weeks as per protocol.
In one case only, the third vaccination was delayed by one week as
a result of low surface expression of CD40L on feeder cells and the
subsequent failure to culture B cells.
Clinical control group
Dogs with multicentric NHL that were treated at the same
institution with the same 20-week combination chemotherapy
protocol and that achieved complete clinical remission confirmed
by restaging were used as a control population for comparison in
the outcome analysis. Information regarding signalment, stage,
immunophenotype (when available), TTP, LSS, use of salvage
therapy, and cause of death were collected and compared to the
vaccine group.
IFN-gamma ELISPOT immune analysis
To amplify antigen-specific T cell responses, cryopreserved
PBMC were thawed, and stimulated with autologous CD40-B
electroporated with either 2 ug CDV mRNA or 10 ug autologous
tumor RNA. 3610
6 PBMC were co-cultured with 5610
5 RNA-
loaded CD40-B cells in 24-well plates as previously described [12].
Cultured were supplemented with 500 U/ml recombinant canine
IL-4 and 10 ng/ml recombinant human IL-7 (Sigma, St. Louis,
MO, USA) on day 0 and 20 U/ml recombinant human IL-2
(Chiron, Emeryville, CA, USA) on days 1 and 4. After 7 days, cells
were harvested and used for ELISPOT (2.5610
4 T cells per well)
as previously described [12]. All samples were performed in
triplicate; for cases in which cell numbers were limiting, samples
were performed in duplicate. Targets were autologous PBMC
stimulated with phytohemagglutinin (PHA, 5 ug/ml) and IL-2 for
5 days, electroporated with either CDV mRNA or total autologous
tumor RNA. Immunospot plates were pre-coated with anti-canine
IFN-c monoclonal antibody (R&D Systems) and incubated at
37uC overnight. Plates were developed according to the
manufacturer’s instructions and spots were counted using a Prior
ProScan analyzer and Image Pro Plus software (Hitech Instru-
ments, Edgemont, PA, USA).
Biostatistics
Continuous data were expressed as means (+/2 SD) and
categorical data as frequencies and percentages. To assess
differences between Groups 1, 2, and 3, Student’s t-test was used
for continuous variables (e.g. age, body weight) and Chi-square or
Fisher’s exact test was used for categorical or binominal variables.
Time to progression (TTP) and lymphoma specific survival (LSS)
were the endpoints evaluated in the outcome analysis, measured
from the first day of chemotherapy to the clinical event in all
groups. Dogs that were lost to follow-up and dogs that died due to
other causes than lymphoma and lymphoma treatment were
censored at the last date of known status or when they died from
other causes, respectively. The Kaplan Meier product limit
method was used to estimate TTP and LSS for all 3 groups.
Censored data was entered into the Kaplan Meier model and
handled as incomplete data for the computations [26]. The log
rank test was used to test for differences between the groups.
Significance was set at p,.05. ELISPOT results pre and post
vaccination were compared using Student’s t-tests. Significance
was set at **p,0.05, and results that approached significance
*p,0.1 were also noted. In cases for which samples could only be
performed in duplicate, p values could not be calculated.
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